Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FTY 720 · 3 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| FTY720 | DRUG | - |
| FTY 720 | DRUG | - |
Inclusion Criteria: * Patients undergoing their first kidney transplant * Male or female age 18 to 65 years Exclusion Criteria: * Patients in need of second kidney transplant or multi-organ transplants.
FTY 720 is an investigational small molecule being studied for renal transplantation, kidney transplantation, asthma, multiple sclerosis, and relapsing multiple sclerosis. It has been evaluated in clinical trials for these conditions, though it remains in development and is not approved.
FTY 720 is being developed by Novartis AG, a company traded on the New York Stock Exchange under the ticker symbol NVS. Novartis has sponsored clinical trials investigating the drug across multiple indications.
FTY 720 has reached Phase 3 clinical development, specifically in a study for relapsing multiple sclerosis. Additional trials in renal transplantation and asthma were conducted in Phase 2. The drug is investigational and not approved.
FTY 720 has been studied in six completed trials, including NCT00239798 and NCT00239902 in renal transplantation, NCT00785083 in asthma, and NCT01127750 in relapsing multiple sclerosis. All trials are completed, with no active studies ongoing.
FTY 720 is also known as fingolimod. It is a small molecule developed by Novartis that has been investigated in clinical trials for conditions such as multiple sclerosis and renal transplantation.